Non-small Cell Lung Cancer

Showing 1 - 25 of 1,515

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Irvine, Chicago, Boston

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Irvine, California
  • +2 more
Nov 27, 2023

Melanoma, NSCLC Trial (Evaluation of ctDNA using the F1T after 1 year of immunotherapy)

Not yet recruiting
  • Melanoma
  • Non-small Cell Lung Cancer
  • Evaluation of ctDNA using the F1T after 1 year of immunotherapy
  • (no location specified)
Nov 24, 2023

GSTP1 and Other Gene Polymorphisms With Platinum-induced

Not yet recruiting
  • Non-small Cell Lung Cancer
  • GSTP1 A313G (AA)
  • (no location specified)
Nov 16, 2023

NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)

Recruiting
  • Non-small Cell Lung Cancer
  • Hypofractionated radiotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun yat-sen university cancer center
Nov 14, 2023

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

NSCLC Trial in Shanghai (Toripalimab, Cryoablation)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 7, 2023

NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
  • placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
  • Tianjing, Tianjin, China
    Tianjin cancer hospital
Nov 3, 2023

NSCLC Trial in Guangzhou (BL-M07D1)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 1, 2023

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

NSCLC, Oligoprogressive, Small-cell Lung Cancer Trial in Sacramento (Ablative local therapy)

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Ablative local therapy
  • Sacramento, California
    University of California, Davis
Oct 27, 2023

Huaier Granules in Postoperative Adjuvant Therapy for Non-small

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Huaier granule
  • Control
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Oct 27, 2023

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tislelizumab IV
  • +2 more
  • (no location specified)
Oct 25, 2023

NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Pembrolizumab co-formulated with hyaluronidase
  • Pembrolizumab
  • (no location specified)
Oct 19, 2023

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

NSCLC Trial (Dupilumab, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Dupilumab
  • Cemiplimab
  • (no location specified)
Oct 12, 2023

NSCLC Trial in Iowa City ([18F]F-ARAG PET)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • [18F]F-ARAG PET
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
Oct 10, 2023

NSCLC Trial in Iowa City (Durvalumab, Pharmacological ascorbate, Surgery (SOC))

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Iowa City, Iowa
    University of Iowa
Oct 10, 2023

NSCLC Trial in Houston (Amivantamab, Tepotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

Recruiting
  • Non-small Cell Lung Cancer
  • SH-1028 tablets
  • Placebo SH-1028 tablets
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Oct 6, 2023

NSCLC Trial (V940, Pembrolizumab, Placebo)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • V940
  • +2 more
  • (no location specified)
Oct 5, 2023

NSCLC Trial in Rockville (Crizotinib - Usual, Crizotinib - Study)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Crizotinib - Usual
  • Crizotinib - Study
  • Rockville, Maryland
    Medicine Invention Design, Inc. - IORG0007849
Oct 5, 2023

NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Nintedanib, gefitinib, erlotinib, afatinib
  • (no location specified)
Oct 2, 2023

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

Recruiting
  • Non-small Cell Lung Cancer
    • Santiago de Compostela, Galicia, Spain
      Luis Ángel Leon Mateos
    Oct 3, 2023

    NSCLC, Neoadjuvant Therapy, Radiotherapy Trial in Yangzhou (drug, radiation, other)

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • Yangzhou, Jiangsu, China
      People's hospital of northern jiangsu
    Sep 26, 2023